Sepsis and septic shock are associated with high morbidity and a very high mortality risk

Sepsis is a common condition that often results in death 38


Globally, mortality of sepsis patients in the ICU is approximately37 33%

over 147 000 cases per year in the UK 38

In Europe, the incidence of severe sepsis is estimated at 90.4 cases per 100 000 population 38

Severe sepsis is very costly to treat, the direct hospital costs in the UK are estimated to be £7,000 38

  • The direct health care costs are estimated to be €8-9 billion in Germany (3% of the entire healthcare budget)
  • The total direct hospital costs are estimated to be up to £1.1 billion in the UK37
  • The number of cases in France is rising47
  • Nearly 15% of patients in intensive care have severe sepsis, two thirds of these are septic shock48
  • The total cost of sepsis, healthcare and societal now estimated to be £7.7 billion in the UK37

Delays in the recognition and diagnosis of sepsis is associated with avoidable patient mortality and morbidity and excess health care costs

  • Faster lab turnaround time can improve outcomes such as reduced Emergency Department (ED) length of stay (LOS), and emergency medical service diversions and better ED throughput  41,42
  • Better recognition of sepsis could save the NHS in England £4,000 per patient in terms of reduced hospital stay which could save £196 million per year 40

£ 4 000 per patient


£ 196m per year

Challenges in Sepsis


High quality blood cultures and diagnostic systems to help identify, type and target treatment of bloodstream infections and Sepsis.

More rapid, accurate and appropriate diagnostic identification to enable more effective clinical decision-making including measures to appropriately isolate and/or target and treat patients.

Sample collection
Improved sample quality resulting in faster and more consistent results, greater diagnostic accuracy, prevention of sample collection errors, and poor quality samples and retesting.

Surveillance and reporting
Using a digital infrastructure to accelerate remote multi-site diagnostic results availability between the lab and second location. Enables faster decisions about antibiotic therapy. Allows for surveillance of epidemiological trends.

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.

Get in touch